• Asthma/COPD

Fasenra Generic Name & Formulations

General Description

Benralizumab 30mg/mL; soln for SC inj; preservative-free.

Pharmacological Class

Interleukin-5 antagonist.

How Supplied

Single-dose prefilled syringe—1; Single-dose autoinjector (pen)—1

Generic Availability


Fasenra Indications


As add-on maintenance treatment of severe asthma in patients ≥12yrs old, and with an eosinophilic phenotype.

Limitations of Use

Not for treating other eosinophilic conditions. Not for relief of acute bronchospasm or status asthmaticus.

Fasenra Dosage and Administration


Give by SC inj into upper arm, thigh, or abdomen. 30mg once every 4 weeks for the first 3 doses, then once every 8 weeks thereafter.


<12yrs: not established.

Fasenra Contraindications

Not Applicable

Fasenra Boxed Warnings

Not Applicable

Fasenra Warnings/Precautions


Not for treating acute asthma symptoms or exacerbations. Discontinue if hypersensitivity reactions occur. Treat pre-existing helminth infections before initiating therapy; discontinue Fasenra if treatment-resistant infection occurs while on therapy until resolves. Avoid abrupt discontinuation of systemic or inhaled corticosteroids; reduce dose gradually upon Fasenra initiation, if appropriate. Reduction may be associated with systemic withdrawal symptoms and/or unmask previously suppressed conditions. Pregnancy. Nursing mothers.

Fasenra Pharmacokinetics

See Literature

Fasenra Interactions

Fasenra Adverse Reactions

Adverse Reactions

Headache, pharyngitis, pyrexia, hypersensitivity reactions.

Fasenra Clinical Trials

See Literature

Fasenra Note

Not Applicable

Fasenra Patient Counseling

See Literature